British Journal of Haematology最新文献

{"title":"Prospective phase I study of nivolumab to promote graft-versus-tumour in relapsed or refractory haematological malignancy post allogeneic haematopoietic stem cell transplantation.","authors":"Trung Q Ngo, Eric Wong, Joanne E Davis, Mandy Ludford-Menting, Jessica Klass, Sara K Dohrmann, Rachel Koldej, David Ritchie","doi":"10.1111/bjh.70883","DOIUrl":"https://doi.org/10.1111/bjh.70883","url":null,"abstract":"<p><p>Allogeneic haematopoietic stem cell transplantation (alloHSCT) relies on donor-derived T cells to mediate the graft-versus-tumour (GVT) effect, but relapse may result from impaired immune reconstitution, tumour antigen downregulation or T-cell exhaustion. This prospective phase I study evaluated the safety and efficacy of the PD-1 inhibitor, nivolumab, in enhancing GVT post-alloHSCT and explored the impact of baseline T-cell phenotypes on clinical outcomes. Fourteen patients with relapsed/refractory haematological malignancies post-alloHSCT received nivolumab every 2 weeks for up to 48 weeks. Six achieved complete remission, all with chronic lymphoid malignancies. Patients with myeloid malignancies or acute lymphoblastic leukaemia had inferior progression-free survival (4.3 vs. 11.7 months, p < 0.05) and overall survival (43.6 months vs. undefined, p < 0.05) than those with chronic lymphoid malignancies. Nine serious adverse events occurred, including four dose-limiting toxicities due to graft-versus-host disease (GVHD) or pneumonitis. Patients who developed GVHD had higher T-cell activation at baseline and achieved early clinical responses. These findings confirm that nivolumab can promote GVT post-alloHSCT, particularly in lymphoid disorders. Baseline immunophenotype (effector memory T cells, Human Leukocyte Antigen - DR isotype [HLA-DR]) and gene expression (granzyme A [GZMA], granzyme B [GZMB], perforin [PRF1]) can be used as biomarkers to help identify patients most likely to benefit from salvage checkpoint inhibition.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced fibrosis, TP53 variants and acute/pure erythroid leukaemia: Diagnostic harbingers of ERCC6L2-related bone marrow failure syndrome?","authors":"Sai Sudha Valisekka,&nbsp;Meghan E. Lindstrom,&nbsp;Olivia J. Michel,&nbsp;Roy L. Kao","doi":"10.1111/bjh.70666","DOIUrl":"10.1111/bjh.70666","url":null,"abstract":"&lt;p&gt;A 27-year-old male presented with neutrophil count 0.8 × 10&lt;sup&gt;9&lt;/sup&gt;/L (reference range: 1.6–8.1), haemoglobin 39 g/L (131–171), platelets 19 × 10&lt;sup&gt;9&lt;/sup&gt;/L (179–450) and fever. Bone marrow (BM) biopsy revealed patchy sheets of large, atypical cells with round to slightly irregular nuclear contours; delicate, open chromatin with inconspicuous nucleoli; and moderate to scant eosinophilic cytoplasm (left, haematoxylin and eosin [H&amp;E], objective ×10). These stained positive for E-cadherin and cluster of differentiation (CD)-43, consistent with erythroid precursors (not shown), and diffuse, strong nuclear p53 expression (not shown). European Consensus grade 3 out of 3 reticulin fibrosis (not shown) precluded precise evaluation of cellularity. Touch imprints (top right, H&amp;E, objective ×50), nearly acellular, showed cells with ovoid nuclei, fine chromatin with prominent nucleoli and scant, deeply basophilic cytoplasm, suggestive of atypical pronormoblasts. Failed cell culture precluded cytogenetic evaluation. Next-generation sequencing identified three pathogenic tumor protein p53 (&lt;i&gt;TP53&lt;/i&gt;) variants. Germline genetic testing on cultured skin fibroblasts revealed a pathogenic homozygous exon 11 deletion in the excision repair cross-complementing 6 like 2 gene (&lt;i&gt;ERCC6L2&lt;/i&gt;), establishing a diagnosis of autosomal recessive &lt;i&gt;ERCC6L2&lt;/i&gt;-related bone marrow failure syndrome.&lt;/p&gt;&lt;p&gt;Despite chemotherapy, he developed a new liver mass. Biopsy showed diffuse predominantly sinusoidal infiltration by large atypical cells with scant cytoplasm and large nuclei containing vesicular chromatin and prominent central nucleoli (bottom right, H&amp;E, objective ×20). These demonstrated dim CD45, patchy E-cadherin, strong CD43 and diffuse, strong CD117 and glucose transporter 1 (GLUT1) expression (not shown), consistent with myeloid blasts with erythroid differentiation (erythroblasts). Diffuse, strong nuclear p53 expression was also present (not shown). Overall, findings were consistent with myeloid sarcoma, arising from acute/pure erythroid leukaemia (AEL/PEL). He eventually died of disease relapse involving BM, liver and pleura despite high-dose cytarabine followed by myeloablative peripheral blood haematopoietic stem cell transplantation from an human leukocyte antigen-matched sibling, a heterozygous carrier for the same &lt;i&gt;ERCC6L2&lt;/i&gt; variant. Genetic counselling for family members was provided.&lt;/p&gt;&lt;p&gt;AEL/PEL in this patient supports emerging evidence that &lt;i&gt;ERCC6L2&lt;/i&gt;-related leukaemias show an association with the erythroid lineage.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; This case also demonstrates the possibility of extra-medullary involvement, including liver and pleural infiltration. The initial early erythroid precursors seen on BM biopsy likely represented blast equivalents for this patient. Together, advanced reticulin fibrosis, erythroid predominance and &lt;i&gt;TP53&lt;/i&gt; mutation may represent a characteristic pathological triad in &lt;i&gt;ERCC6L2&lt;/i&gt;-re","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 4","pages":"1444-1445"},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.70666","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148402992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The leukaemia in pregnancy study, a national multicentre retrospective study of pregnancy outcomes in women with concurrent or historic diagnoses of acute leukaemia.","authors":"Lukas Pitel, Matthew Northgraves, Judith Cohen, Chao Huang, John Turgoose, Simone Green, Steve Knapper, Gail Jones, Sarah Essex, Julie Kenny, Mhairi Copland, Panagiotis D Kottaridis, Anjum Khan, Sahra Ali, David Allsup","doi":"10.1111/bjh.70876","DOIUrl":"https://doi.org/10.1111/bjh.70876","url":null,"abstract":"<p><p>The leukaemia in pregnancy study was a multicentre retrospective study of pregnancy outcomes of women with concurrent (CAL) or previous (PAL) acute leukaemia. Cases were identified from eight hospitals. Of 39 screened cases, 12 CAL and 21 PAL cases were described, with one belonging to both groups. In the CAL cohort, there were 12 pregnancies with 10 infants delivered, one induced abortion and one unknown outcome. Six of 10 CAL women delivered prior to chemotherapy, two received chemotherapy both antenatally and postnatally, and in two, information was not available. All 10 infants were alive 28 days post-delivery. In the PAL group, 25 pregnancies were identified with 23 deliveries (two with twins), one miscarriage and one with unknown outcomes. Pregnancy complications were reported in four women. Twenty-four of 25 infants were alive 28 days after delivery with one unknown status. Acute leukaemia diagnosed during pregnancy was generally managed with expedited delivery. Neonates born to women with CAL had low birthweights and were premature. Most PAL neonates were born with a normal birthweight and no obstetric complications. For PAL, pregnancy outcomes are comparable to those of the general population.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel biomarkers for the differential diagnosis of paediatric MYH9-related diseases and immune thrombocytopenia revealed by plasma proteomics","authors":"Xiaojuan Luo,&nbsp;Ke Cao,&nbsp;Ruizhi Wang,&nbsp;Weigen Wu,&nbsp;Tao Huang,&nbsp;Yan Zhang,&nbsp;Xiaoying Fu,&nbsp;Defa Li,&nbsp;Meifang He","doi":"10.1111/bjh.70720","DOIUrl":"10.1111/bjh.70720","url":null,"abstract":"<div>\u0000 \u0000 <p>Differentiating myosin heavy chain 9 (MYH9)-related disease (MYH9-RD) from immune thrombocytopenia (ITP) remains clinically challenging. This study utilized data-independent acquisition (DIA) plasma proteomics to identify distinguishing biomarker signatures. Profiling cohorts of MYH9-RD (<i>n</i> = 10), ITP (<i>n</i> = 10) and healthy controls (<i>n</i> = 14) quantified 2533 proteins, revealing distinct immune and metabolic remodelling. We identified 91 MYH9-RD-specific and 124 ITP-specific proteins, highlighting divergent organ involvement pathways. By integrating protein–protein interaction networks with Boruta and Random Forest machine-learning algorithms, we identified preliminary candidate biomarker panels (MYH9-RD panel: von Willebrand factor [VWF], cholesteryl ester transfer protein [CETP], apolipoprotein A-1 [APOA1], periostin [POSTN]; ITP panel: neutrophil gelatinase-associated lipocalin [NGAL], plasminogen activator inhibitor-1 [PAI-1], carboxypeptidase B2 [CPB2]) that demonstrated excellent apparent discrimination. This exploratory study provides a hypothesis-generating framework, revealing fundamentally distinct molecular landscapes between congenital and acquired macrothrombocytopenia. Pending rigorous future external validation, these preliminary candidate biomarkers offer novel biological insights into the divergent pathophysiologies of MYH9-RD and ITP.</p>\u0000 </div>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 4","pages":"1598-1609"},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148596969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pure erythroid leukaemia in early infancy: Diagnostic pitfalls and clinical challenges","authors":"Riccardo De Carli,&nbsp;Baptiste Le Calvez,&nbsp;Elodie Lainey,&nbsp;Catherine Settegrana,&nbsp;Marion Strullu,&nbsp;Marlene Pouthier","doi":"10.1111/bjh.70665","DOIUrl":"10.1111/bjh.70665","url":null,"abstract":"&lt;p&gt;A 2-month-old boy, born to non-consanguineous parents, with no relevant personal or family medical history, was admitted for recurrent vomiting and afebrile clonic seizures involving the right lower limb. Physical examination revealed a periorbital haematomа and marked hepatomegaly, without focal neurological deficit.&lt;/p&gt;&lt;p&gt;Initial laboratory investigations showed anaemia (haemoglobin 88 g/L, reference range 100–140 g/L), leucocytosis (white blood cell count 25 × 10&lt;sup&gt;9&lt;/sup&gt;/L, reference range 6–18 × 10&lt;sup&gt;9&lt;/sup&gt;/L; neutrophils 6.6 × 10&lt;sup&gt;9&lt;/sup&gt;/L, reference range 1–8 × 10&lt;sup&gt;9&lt;/sup&gt;/L, without circulating blasts) and thrombocytopenia (platelet count 95 × 10&lt;sup&gt;9&lt;/sup&gt;/L, reference range 150–600 × 10&lt;sup&gt;9&lt;/sup&gt;/L), associated with spontaneous tumour lysis syndrome and disseminated intravascular coagulation.&lt;/p&gt;&lt;p&gt;Whole-body MRI (magnetic resonance imaging) demonstrated (bottom left and right) multiple nodular lesions involving the meninges, bones, facial soft tissues, liver, peritoneum and lungs, without adrenal or retroperitoneal masses.&lt;/p&gt;&lt;p&gt;Bone marrow aspirate (top left) revealed a massive infiltration by proerythroblasts with round nuclei, fine chromatin and abundant deeply basophilic cytoplasm, sometimes vacuolated and displaying characteristic rounded cytoplasmic protrusions. Flow cytometric immunophenotyping (top right) showed high expression of cluster of differentiation (CD) 36 with CD71; CD235a (glycophorin A); CD43, CD58, CD7 and CD9 positivity; partial CD117 expression; dim human leukocyte antigen-DR (HLA-DR); and absence of CD33, CD41, CD42a and thrombopoietin receptor, supporting the diagnosis of pure erythroid leukaemia (PEL).&lt;/p&gt;&lt;p&gt;Conventional cytogenetic analysis revealed a complex karyotype: 47,XY,t(2;6)(q24;q26),+7[20]. Targeted next-generation sequencing of myeloid malignancy-associated genes and RNA (ribonucleic acid) sequencing detected no pathogenic variants. However, copy number gains involving &lt;i&gt;SBDS&lt;/i&gt; (SBDS ribosome maturation factor), &lt;i&gt;BRAF&lt;/i&gt; (B-Raf proto-oncogene) and &lt;i&gt;EZH2&lt;/i&gt; (Enhancer of zest homolog 2) were detected.&lt;/p&gt;&lt;p&gt;Induction chemotherapy with mitoxantrone and cytarabine was administered; gemtuzumab ozogamicin was omitted due to the absence of CD33 expression. Induction therapy failed to achieve remission, and no salvage treatment could be administered because of severe treatment-related toxicity. The patient died from refractory disease with central nervous system progression 2 months after treatment initiation.&lt;/p&gt;&lt;p&gt;PEL is a rare and highly aggressive subtype of acute myeloid leukaemia that predominantly affects older adults and is exceptional in infants. It is typically associated with complex cytogenetics and &lt;i&gt;TP53&lt;/i&gt; alterations, while lacking many recurrent mutations commonly observed in myeloid neoplasms. However, emerging data suggest that paediatric cases may harbour distinct molecular features.&lt;span&gt;&lt;sup&gt;1-3&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;Overall prognosis remains extremely poor&lt;s","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":"209 4","pages":"1442-1443"},"PeriodicalIF":3.6,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.70665","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148672881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frailty and quality of life in a real-world multiple myeloma population.","authors":"Klara F K Rydahl, Sören Möller, Trine Allerslev Horsbøl, Birgit Bjerre Høyer, Bo Amdi Jensen, Carsten Helleberg, Anja Klostergaard, Henrik Gregersen, Sarah Farmer, Mikael Frederiksen, Anne Kærsgaard Mylin, Morten Saaby Steffensen, Per Trøllund Pedersen, Ida Bruun Kristensen, Niels Abildgaard, Lene Kongsgaard Nielsen","doi":"10.1111/bjh.70870","DOIUrl":"https://doi.org/10.1111/bjh.70870","url":null,"abstract":"<p><p>Frailty is common in multiple myeloma (MM) and is associated with inferior outcomes. Knowledge on quality of life (QoL) primarily originates from clinical trials, where frail patients are often not included. In this nationwide, longitudinal observational study, QoL was assessed in 681 Danish patients with newly diagnosed MM (NDMM) or relapsed or refractory MM (RRMM) with symptomatic disease using patient-reported outcomes collected over 2 years of follow-up between 2017 and 2021. Patients were categorized as fit, intermediate-fit or frail according to the International Myeloma Working Group (IMWG) frailty score. Preselected QoL domains from the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 (QLQ-C30), the Chemotherapy-Induced Peripheral Neuropathy module (EORTC QLQ-CIPN20) and the Short-form health survey (SF12) questionnaires were analysed using linear mixed models and interpreted in terms of clinical relevance. At inclusion, frail patients reported clinically relevant lower global QoL and physical functioning, and more fatigue compared to fit patients. Frail NDMM patients reported improvement in global QoL and pain during follow-up, whereas physical functioning and fatigue remained unchanged. Frail RRMM patients reported unchanged global QoL and fatigue, and deterioration in physical functioning and more pain during follow-up. Our results based on a real-world population show that QoL findings from clinical trial populations cannot directly be applied to frail patients.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase 3, randomised, placebo-controlled trial of voxelotor for the resolution of leg ulcers in sickle cell disease: RESOLVE.","authors":"Bernhards Ogutu, Janet Oyieko, Halima Bello-Manga, Adeseye Akinsete, Jessie Githanga, José Valber Lima Meneses, Carolyn Hoppe, Mark W Davis, Jeremy Rupon, Ching-Ray Yu, Roberto Pinto, Elena Tudone, Ibrahim Musa Idris, Martin Meremikwu, Aderson da Silva Araújo, Rodolfo D Cançado, Guilherme Fonseca, Patrícia Santos Resende Cardoso, Obiageli Eunice Nnodu","doi":"10.1111/bjh.70856","DOIUrl":"https://doi.org/10.1111/bjh.70856","url":null,"abstract":"<p><p>Leg ulcers are a debilitating complication of sickle cell disease (SCD, including sickle cell anaemia and other sickle cell disorders) and have no proven treatments. Resolution of Sickle Cell Leg Ulcers with Voxelotor (RESOLVE) was a Phase 3, randomised, double-blind, placebo-controlled trial evaluating voxelotor for leg ulcer resolution in participants aged ≥12 years with SCD (homozygous haemoglobin S [HbSS]/haemoglobin S β⁰-thalassaemia [HbSβ⁰]) and ≥1 active cutaneous lower-extremity ulcer. Participants from Kenya, Nigeria and Brazil were randomised 1:1 to voxelotor 1500 mg (N = 45) or placebo (N = 43) for 12 weeks. The primary end-point, complete resolution of all target ulcer(s) at Week 12, was not met (achieved resolution: voxelotor 6.7% [3/45], placebo 7.0% [3/43]; two-sided p > 0.99). After Week 12, both groups received open-label voxelotor. During this period, dosing was paused in May 2024, when preliminary data from four voxelotor trials, including RESOLVE, showed safety signals and potential risks that required further analysis. The trial was discontinued in September 2024 when voxelotor was withdrawn from all markets globally. In final safety analyses for RESOLVE, the most common SCD-related treatment-emergent adverse event (TEAE) was sickle cell anaemia with crisis (randomised period: voxelotor 44.4%, placebo 25.6%; open-label period: continuing-voxelotor 60.5%, delayed-voxelotor 53.5%). Eleven participants had fatal events, nine when receiving voxelotor and two after voxelotor was paused (one after ~1 week; one after ~4 months); no deaths were considered treatment-related. In conclusion, leg ulcer resolution was similar between groups, and the voxelotor arm had a higher rate of TEAEs.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repertoire diversity and dynamics of peripheral Th17 after allogeneic haematopoietic stem cell transplantation.","authors":"Masaharu Tamaki, Hideki Nakasone, Shunto Kawamura, Kosuke Takano, Yukiko Misaki, Kazuki Yoshimura, Yosuke Okada, Aki Tanihara, Koki Hashino, Kaisuke Yamamoto, Yuya Nakata, Takuto Ishikawa, Akari Matsuoka, Tomohiro Meno, Yuhei Nakamura, Masakatsu Kawamura, Junko Takeshita, Nozomu Yoshino, Ayumi Gomyo, Machiko Kusuda, Shun-Ichi Kimura, Shinichi Kako, Yoshinobu Kanda","doi":"10.1111/bjh.70881","DOIUrl":"https://doi.org/10.1111/bjh.70881","url":null,"abstract":"<p><p>Th17, a subset of helper T cells that produce interleukin-17 (IL-17), is thought to play a pivotal role in the pathogenesis of chronic graft-versus-host disease (GVHD). However, the kinetics of Th17 following allogeneic haematopoietic stem cell transplantation (allo-HSCT) have not been elucidated. In this study, we evaluated the temporal dynamics and diversity of peripherally circulating Th17 after allo-HSCT. The study included 86 patients who survived without disease relapse for 1 year or more, and for whom peripheral blood samples 3 months after allo-HSCT were available. Th17 was detected and sorted by flow cytometry, and T-cell receptor (TCR) repertoire was analysed by a next-generation sequencing (NGS) method. Patients with chronic GVHD showed a higher TCR repertoire diversity, while those with severe chronic GVHD showed a lower TCR diversity and Th17/Cluster of Differentiation (CD) 4 ratio. The amino acid sequence in complementarity determining region 3 of Th17-TCR was not apparently different between patients with and without chronic GVHD. Additionally, a higher Th17/CD4 ratio at 3 months was related to a lower incidence of subsequent chronic GVHD. The current study explored the kinetics of peripherally circulating Th17 after allo-HSCT, which might be associated with the development of chronic GVHD.</p>","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between chronic kidney disease and the risk of myelodysplastic syndromes: A large claims database study in Japan.","authors":"Yuta Baba, Takehiko Sambe, Tetsuya Fukuda, Tatsunori Oguchi, Kenji Momo","doi":"10.1111/bjh.70885","DOIUrl":"https://doi.org/10.1111/bjh.70885","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma.","authors":"Leah A Goldberg, Anjani D Kapadia, Andrew S Palmer, Lydia Benitez Colon, Bernard L Marini, Anthony J Perissinotti, Dale L Bixby, Patrick W Burke, Syed Abdul Mannan Shah, Hamed Rahmani Youshanlouei, Adam S DuVall, John F Cursio, Wendy Stock, Emily Dworkin, Anand A Patel","doi":"10.1111/bjh.70887","DOIUrl":"https://doi.org/10.1111/bjh.70887","url":null,"abstract":"","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149190310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}